<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39337454</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9966</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25189966</ELocationID><Abstract><AbstractText>This review offers an in-depth examination of amyotrophic lateral sclerosis (ALS), addressing its epidemiology, pathophysiology, clinical presentation, diagnostic techniques, and current as well as emerging treatments. The purpose is to condense key findings and illustrate the complexity of ALS, which is shaped by both genetic and environmental influences. We reviewed the literature to discuss recent advancements in understanding molecular mechanisms such as protein misfolding, mitochondrial dysfunction, oxidative stress, and axonal transport defects, which are critical for identifying potential therapeutic targets. Significant progress has been made in refining diagnostic criteria and identifying biomarkers, leading to earlier and more precise diagnoses. Although current drug treatments provide some benefits, there is a clear need for more effective therapies. Emerging treatments, such as gene therapy and stem cell therapy, show potential in modifying disease progression and improving the quality of life for ALS patients. The review emphasizes the importance of continued research to address challenges such as disease variability and the limited effectiveness of existing treatments. Future research should concentrate on further exploring the molecular foundations of ALS and developing new therapeutic approaches. The implications for clinical practice include ensuring the accessibility of new treatments and that healthcare systems are equipped to support ongoing research and patient care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizea</LastName><ForeName>Radu Eugen</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-3848-0893</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, "Bagdasar-Arseni" Clinical Emergency Hospital, 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corlatescu</LastName><ForeName>Antonio-Daniel</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0009-0007-9232-1176</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costin</LastName><ForeName>Horia Petre</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0002-6347-9958</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitru</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3784-7355</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Morphopathology, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency University Hospital Bucharest, 050098 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciurea</LastName><ForeName>Alexandru Vlad</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanador Clinical Hospital, 010991 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">stem cell therapy</Keyword><Keyword MajorTopicYN="N">therapeutic approaches</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337454</ArticleId><ArticleId IdType="pmc">PMC11432652</ArticleId><ArticleId IdType="doi">10.3390/ijms25189966</ArticleId><ArticleId IdType="pii">ijms25189966</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ryan M., Heverin M., McLaughlin R.L., Hardiman O. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2019;76:1367&#x2013;1374. doi: 10.1001/jamaneurol.2019.2044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:480&#x2013;493. doi: 10.1016/S1474-4422(21)00465-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D., Morren J.A., Pioro E.P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 2020;417:117054. doi: 10.1016/j.jns.2020.117054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.-M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Parobkova E., Matej R. Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degenerations: Similarities in Genetic Background. Diagnostics. 2021;11:509. doi: 10.3390/diagnostics11030509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11030509</ArticleId><ArticleId IdType="pmc">PMC7998502</ArticleId><ArticleId IdType="pubmed">33805659</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Fontana A., Arcuti S., Copetti M., Boum&#xe9;diene F., Couratier P., Beghi E., Preux P.M., Logroscino G. Age-specific ALS incidence: A dose&#x2013;response meta-analysis. Eur. J. Epidemiol. 2018;33:621&#x2013;634. doi: 10.1007/s10654-018-0392-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-018-0392-x</ArticleId><ArticleId IdType="pubmed">29687175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Kaye W., Raymond J., Punjani R., Larson T., Cohen J., Muravov O., Horton K. Prevalence of Amyotrophic Lateral Sclerosis&#x2014;United States, 2015. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1285&#x2013;1289. doi: 10.15585/mmwr.mm6746a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna J., Diagana M., Ait Aissa L., Tazir M., Ali Pacha L., Kacem I., Gouider R., Henning F., Basse A., Cisse O., et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: The TROPALS study. J. Neurol. Neurosurg. Psychiatry. 2019;90:20&#x2013;29. doi: 10.1136/jnnp-2018-318469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318469</ArticleId><ArticleId IdType="pubmed">30242088</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2017 US Neurological Disorders Collaborators. Feigin V.L., Vos T., Alahdab F., Amit A.M.L., B&#xe4;rnighausen T.W., Beghi E., Beheshti M., Chavan P.P., Criqui M.H., et al. Burden of Neurological Disorders Across the US from 1990&#x2013;2017: A Global Burden of Disease Study. JAMA Neurol. 2021;78:165&#x2013;176. doi: 10.1001/jamaneurol.2020.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4152</ArticleId><ArticleId IdType="pmc">PMC7607495</ArticleId><ArticleId IdType="pubmed">33136137</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liu T., Liu L., Yao X., Chen L., Fan D., Zhan S., Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. 2020;267:944&#x2013;953. doi: 10.1007/s00415-019-09652-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowland A., Opie-Martin S., Scott K.M., Jones A.R., Mehta P.R., Batts C.J., Ellis C.M., Leigh P.N., Shaw C.E., Sreedharan J., et al. Predicting the future of ALS: The impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020&#x2013;2116. Amyotroph. Lateral Scler. Front. Degener. 2019;20:264&#x2013;274. doi: 10.1080/21678421.2019.1587629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587629</ArticleId><ArticleId IdType="pmc">PMC6567553</ArticleId><ArticleId IdType="pubmed">30961394</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana A., Marin B., Luna J., Beghi E., Logroscino G., Boum&#xe9;diene F., Preux P.-M., Couratier P., Copetti M. Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: A dose-response meta-analysis. J. Neurol. 2021;268:2973&#x2013;2984. doi: 10.1007/s00415-021-10464-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10464-2</ArticleId><ArticleId IdType="pubmed">33630135</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy N.A., Arthur K.C., Tienari P.J., Houlden H., Chi&#xf2; A., Traynor B.J. Age-related penetrance of the C9orf72 repeat expansion. Sci. Rep. 2017;7:2116. doi: 10.1038/s41598-017-02364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A., Manera U., D&#x2019;Ovidio F., Vasta R., Grassano M., Brunetti M., Barberis M., Corrado L., et al. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. 2020;94:e802&#x2013;e810. doi: 10.1212/WNL.0000000000008869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Raymond J., Punjani R., Han M., Larson T., Kaye W., Nelson L.M., Topol B., Muravov O., Genson C., et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph. Lateral Scler. Front. Degener. 2023;24:108&#x2013;116. doi: 10.1080/21678421.2022.2059380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2059380</ArticleId><ArticleId IdType="pmc">PMC9568617</ArticleId><ArticleId IdType="pubmed">35422180</ArticleId></ArticleIdList></Reference><Reference><Citation>Saceleanu V.M., Toader C., Ples H., Covache-Busuioc R.-A., Costin H.P., Bratu B.-G., Dumitrascu D.-I., Bordeianu A., Corlatescu A.D., Ciurea A.V. Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations. Biomedicines. 2023;11:2617. doi: 10.3390/biomedicines11102617.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11102617</ArticleId><ArticleId IdType="pmc">PMC10604797</ArticleId><ArticleId IdType="pubmed">37892991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury J.J., Ooi L., Dillin A., Saunders D.N., Hatters D.M., Beart P.M., Cashman N.R., Wilson M.R., Ecroyd H. Walking the tightrope: Proteostasis and neurodegenerative disease. J. Neurochem. 2016;137:489&#x2013;505. doi: 10.1111/jnc.13575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13575</ArticleId><ArticleId IdType="pubmed">26872075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohl C., Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818&#x2013;822. doi: 10.1126/science.aax3769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax3769</ArticleId><ArticleId IdType="pubmed">31727826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A., Kwon Y.T. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp. Mol. Med. 2015;47:e147. doi: 10.1038/emm.2014.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.117</ArticleId><ArticleId IdType="pmc">PMC4351408</ArticleId><ArticleId IdType="pubmed">25766616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Fan H., Ying Z., Li B., Wang H., Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci. Lett. 2010;469:112&#x2013;116. doi: 10.1016/j.neulet.2009.11.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.11.055</ArticleId><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J., Al Sultan A., Waller R., Heath P. The genetics of amyotrophic lateral sclerosis: Current insights. DNND. 2016;2016:49&#x2013;64. doi: 10.2147/DNND.S84956.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S84956</ArticleId><ArticleId IdType="pmc">PMC6053097</ArticleId><ArticleId IdType="pubmed">30050368</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol. Clin. 2015;33:807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Fang F., Hanby M.F., Leigh P.N., Shaw C.E., Ye W., Rijsdijk F. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry. 2010;81:1324&#x2013;1326. doi: 10.1136/jnnp.2010.207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S., Shatunov A., Sproviero W., Jones A.R., Shoai M., Hughes D., Al Khleifat A., Malaspina A., Morrison K.E., Shaw P.J., et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611&#x2013;1618. doi: 10.1093/brain/awx082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx082</ArticleId><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Voicu V., Brehar F.-M., Toader C., Covache-Busuioc R.-A., Corlatescu A.D., Bordeianu A., Costin H.P., Bratu B.-G., Glavan L.-A., Ciurea A.V. Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy. Biomolecules. 2023;13:1388. doi: 10.3390/biom13091388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13091388</ArticleId><ArticleId IdType="pmc">PMC10526757</ArticleId><ArticleId IdType="pubmed">37759788</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers J., Banchi E.-G., Latouche M. C9ORF72: What It Is, What It Does, and Why It Matters. Front. Cell. Neurosci. 2021;15:661447. doi: 10.3389/fncel.2021.661447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId><ArticleId IdType="pmc">PMC8131521</ArticleId><ArticleId IdType="pubmed">34025358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Ravits J. Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Neurotherapeutics. 2019;16:1115&#x2013;1132. doi: 10.1007/s13311-019-00797-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00797-2</ArticleId><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Y., Cai Q. Role of C9orf72 hexanucleotide repeat expansions in ALS/FTD pathogenesis. Front. Mol. Neurosci. 2024;17:1322720. doi: 10.3389/fnmol.2024.1322720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2024.1322720</ArticleId><ArticleId IdType="pmc">PMC10838790</ArticleId><ArticleId IdType="pubmed">38318532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C., Corcia P., Vourc&#x2019;h P., Dupuis L. C9ORF72 hexanucleotide repeat expansion: From ALS and FTD to a broader pathogenic role? Rev. Neurol. 2024;180:417&#x2013;428. doi: 10.1016/j.neurol.2024.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2024.03.008</ArticleId><ArticleId IdType="pubmed">38609750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler R., Traynor B.J., Robertson J., Van Den Bosch L., Barmada S.J., Svendsen C.N., Disney M.D., Gendron T.F., Wong P.C., Turner M.R., et al. Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit. Neurol. Ther. 2023;12:1821&#x2013;1843. doi: 10.1007/s40120-023-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-023-00548-8</ArticleId><ArticleId IdType="pmc">PMC10630271</ArticleId><ArticleId IdType="pubmed">37847372</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Jiao B., Shen L. The Development of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disorders. Front. Genet. 2020;11:562758. doi: 10.3389/fgene.2020.562758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.562758</ArticleId><ArticleId IdType="pmc">PMC7492664</ArticleId><ArticleId IdType="pubmed">32983232</ArticleId></ArticleIdList></Reference><Reference><Citation>Boncella A.E., Shattuck J.E., Cascarina S.M., Paul K.R., Baer M.H., Fomicheva A., Lamb A.K., Ross E.D. Composition-based prediction and rational manipulation of prion-like domain recruitment to stress granules. Proc. Natl. Acad. Sci. USA. 2020;117:5826&#x2013;5835. doi: 10.1073/pnas.1912723117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1912723117</ArticleId><ArticleId IdType="pmc">PMC7084078</ArticleId><ArticleId IdType="pubmed">32127480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Keyhanian K., Douthwright C. Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Cells. 2021;10:249. doi: 10.3390/cells10020249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020249</ArticleId><ArticleId IdType="pmc">PMC7912327</ArticleId><ArticleId IdType="pubmed">33525344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang W., Hu F. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J. Neurochem. 2021;157:334&#x2013;350. doi: 10.1111/jnc.15255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15255</ArticleId><ArticleId IdType="pmc">PMC8842544</ArticleId><ArticleId IdType="pubmed">33259633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer C.S., Cohen R.N., Sironi F., Livesey M.R., Gillingwater T.H., Highley J.R., Fillingham D.J., Coldicott I., Smith E.F., Gibson Y.B., et al. An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD. Acta Neuropathol. 2022;144:437&#x2013;464. doi: 10.1007/s00401-022-02470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02470-z</ArticleId><ArticleId IdType="pmc">PMC9381633</ArticleId><ArticleId IdType="pubmed">35876881</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P., Lau A., You Z., Durcan T.M., Robertson J. Loss of C9orf72 perturbs the Ran-GTPase gradient and nucleocytoplasmic transport, generating compositionally diverse Importin &#x3b2;-1 granules. Cell Rep. 2023;42:112134. doi: 10.1016/j.celrep.2023.112134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112134</ArticleId><ArticleId IdType="pubmed">36821445</ArticleId></ArticleIdList></Reference><Reference><Citation>Celona B., Salomonsson S.E., Wu H., Dang B., Kratochvil H.T., Clelland C.D., DeGrado W.F., Black B.L. Zfp106 binds to G-quadruplex RNAs and inhibits RAN translation and formation of RNA foci caused by G4C2 repeats. Proc. Natl. Acad. Sci. USA. 2024;121:e2220020121. doi: 10.1073/pnas.2220020121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2220020121</ArticleId><ArticleId IdType="pmc">PMC11295049</ArticleId><ArticleId IdType="pubmed">39042693</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., Sun S., Herdy J.R., Bieri G., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Michiels E., Gijselinck I., Sieben A., Jovi&#x10d;i&#x107; A., De Baets G., Scheveneels W., Steyaert J., Cuijt I., et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 2016;6:20877. doi: 10.1038/srep20877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20877</ArticleId><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.R., Duan L., Bowen K., Kalab P., Rothstein J.D. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. eLife. 2020;9:e51685. doi: 10.7554/eLife.51685.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.51685</ArticleId><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.-B. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade N.S., Ramic M., Esanov R., Liu W., Rybin M.J., Gaidosh G., Abdallah A., Del&#x2019;Olio S., Huff T.C., Chee N.T., et al. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol. Neurodegener. 2020;15:13. doi: 10.1186/s13024-020-00365-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00365-9</ArticleId><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens T.G., Niccoli T., Wilson K.M., Atilano M.L., Birsa N., Gittings L.M., Holbling B.V., Dyson M.C., Thoeng A., Neeves J., et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 2019;137:487&#x2013;500. doi: 10.1007/s00401-018-1946-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1946-4</ArticleId><ArticleId IdType="pmc">PMC6514073</ArticleId><ArticleId IdType="pubmed">30604225</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Kovacs D., Konijnenberg A., Timmerman E., Volkov A., Guharoy M., De Decker M., Jaspers T., Ryan V.H., et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Mol. Cell. 2017;65:1044&#x2013;1055.e5. doi: 10.1016/j.molcel.2017.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Lin S., Staats K.A., Li Y., Chang W.-H., Hung S.-T., Hendricks E., Linares G.R., Wang Y., Son E.Y., et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325. doi: 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Boivin M., Pfister V., Gaucherot A., Ruffenach F., Negroni L., Sellier C., Charlet-Berguerand N. Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. EMBO J. 2020;39:e100574. doi: 10.15252/embj.2018100574.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100574</ArticleId><ArticleId IdType="pmc">PMC7024836</ArticleId><ArticleId IdType="pubmed">31930538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q., Jiang J., Gendron T.F., McAlonis-Downes M., Jiang L., Taylor A., Diaz Garcia S., Ghosh Dastidar S., Rodriguez M.J., King P., et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci. 2020;23:615&#x2013;624. doi: 10.1038/s41593-020-0619-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0619-5</ArticleId><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H., Lloyd T.E. Disrupted endoplasmic reticulum-mediated autophagosomal biogenesis in a Drosophila model of C9-ALS-FTD. Autophagy. 2024;20:94&#x2013;113. doi: 10.1080/15548627.2023.2249750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2023.2249750</ArticleId><ArticleId IdType="pmc">PMC10761023</ArticleId><ArticleId IdType="pubmed">37599467</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Xu J. C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons. J. Neurosci. 2018;38:7741&#x2013;7752. doi: 10.1523/JNEUROSCI.0908-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0908-18.2018</ArticleId><ArticleId IdType="pmc">PMC6705968</ArticleId><ArticleId IdType="pubmed">30037833</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk T.R., Rousseaux M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Voicu V., Tataru C.P., Toader C., Covache-Busuioc R.-A., Glavan L.A., Bratu B.-G., Costin H.P., Corlatescu A.D., Ciurea A.V. Decoding Neurodegeneration: A Comprehensive Review of Molecular Mechanisms, Genetic Influences, and Therapeutic Innovations. Int. J. Mol. Sci. 2023;24:13006. doi: 10.3390/ijms241613006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241613006</ArticleId><ArticleId IdType="pmc">PMC10455143</ArticleId><ArticleId IdType="pubmed">37629187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde K.N., Srivastava A. Drosophila melanogaster as a Tool for Amyotrophic Lateral Sclerosis Research. J. Dev. Biol. 2022;10:36. doi: 10.3390/jdb10030036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jdb10030036</ArticleId><ArticleId IdType="pmc">PMC9505035</ArticleId><ArticleId IdType="pubmed">36135369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Deng J., Dong J., Liu J., Bigio E.H., Mesulam M., Wang T., Sun L., Wang L., Lee A.Y.-L., et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Eleutherio E.C.A., Silva Magalh&#xe3;es R.S., De Ara&#xfa;jo Brasil A., Monteiro Neto J.R., De Holanda Paranhos L. SOD1, more than just an antioxidant. Arch. Biochem. Biophys. 2021;697:108701. doi: 10.1016/j.abb.2020.108701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2020.108701</ArticleId><ArticleId IdType="pubmed">33259795</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J.H. ALS genetic epidemiology &#x2018;How simplex is the genetic epidemiology of ALS?&#x2019;. J. Neurol. Neurosurg. Psychiatry. 2017;88:537. doi: 10.1136/jnnp-2016-315469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315469</ArticleId><ArticleId IdType="pubmed">28209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Layalle S., They L., Ourghani S., Raoul C., Soustelle L. Amyotrophic Lateral Sclerosis Genes in Drosophila melanogaster. Int. J. Mol. Sci. 2021;22:904. doi: 10.3390/ijms22020904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020904</ArticleId><ArticleId IdType="pmc">PMC7831090</ArticleId><ArticleId IdType="pubmed">33477509</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F., Alberti F., Amadio S., Angelini D.F., Pilesi E., Vitale G., Tesoriere G., Borsellino G., Vern&#xec; F., Volont&#xe9; C. Pan-neuronal expression of human mutant SOD1 in Drosophila impairs survival and motor performance, induces early neuroinflammation and chromosome aberrations. Biochim. Et Biophys. Acta (BBA)&#x2014;Mol. Basis Dis. 2024;1870:167192. doi: 10.1016/j.bbadis.2024.167192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2024.167192</ArticleId><ArticleId IdType="pubmed">38657911</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Nesci V., Salvatori I., Fenili G., Rosina M., Gloriani M., Paronetto M.P., Madaro L., Ferri A., Valle C. Endurance exercise has a negative impact on the onset of SOD1-G93A ALS in female mice and affects the entire skeletal muscle-motor neuron axis. Front. Pharmacol. 2024;15:1360099. doi: 10.3389/fphar.2024.1360099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1360099</ArticleId><ArticleId IdType="pmc">PMC10999529</ArticleId><ArticleId IdType="pubmed">38590640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jutzi D., Campagne S., Schmidt R., Reber S., Mechtersheimer J., Gypas F., Schweingruber C., Colombo M., Von Schroetter C., Loughlin F.E., et al. Aberrant interaction of FUS with the U1 snRNA provides a molecular mechanism of FUS induced amyotrophic lateral sclerosis. Nat. Commun. 2020;11:6341. doi: 10.1038/s41467-020-20191-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20191-3</ArticleId><ArticleId IdType="pmc">PMC7733473</ArticleId><ArticleId IdType="pubmed">33311468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanneste J., Van Den Bosch L. The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:12175. doi: 10.3390/ijms222212175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212175</ArticleId><ArticleId IdType="pmc">PMC8620263</ArticleId><ArticleId IdType="pubmed">34830069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A., Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138:95&#x2013;111. doi: 10.1111/jnc.13625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13625</ArticleId><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C., Onesto E., Buratti E., De La Grange P., Gumina V., Baralle F.E., Silani V., Ratti A. From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models. Biochim. Et Biophys. Acta (BBA)&#x2014;Gene Regul. Mech. 2015;1849:1398&#x2013;1410. doi: 10.1016/j.bbagrm.2015.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagrm.2015.10.015</ArticleId><ArticleId IdType="pubmed">26514432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y., Huang E.J. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016;1647:65&#x2013;78. doi: 10.1016/j.brainres.2016.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.03.036</ArticleId><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>Assoni A.F., Foijer F., Zatz M. Amyotrophic Lateral Sclerosis, FUS and Protein Synthesis Defects. Stem Cell Rev. Rep. 2023;19:625&#x2013;638. doi: 10.1007/s12015-022-10489-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-022-10489-8</ArticleId><ArticleId IdType="pubmed">36515764</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y.C., Ng C.S., Xiang P., Liu H., Zhang K., Mohamud Y., Luo H. Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2020;13:78. doi: 10.3389/fnmol.2020.00078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00078</ArticleId><ArticleId IdType="pmc">PMC7273501</ArticleId><ArticleId IdType="pubmed">32547363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes E., Shorter J. The molecular language of membraneless organelles. J. Biol. Chem. 2019;294:7115&#x2013;7127. doi: 10.1074/jbc.TM118.001192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.TM118.001192</ArticleId><ArticleId IdType="pmc">PMC6509512</ArticleId><ArticleId IdType="pubmed">30045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Baradaran-Heravi Y., Van Broeckhoven C., Van Der Zee J. Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiol. Dis. 2020;134:104639. doi: 10.1016/j.nbd.2019.104639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104639</ArticleId><ArticleId IdType="pubmed">31626953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N., Eshleman N., Buchan J.R. Stress Granules and ALS: A Case of Causation or Correlation? In: Sattler R., Donnelly C.J., editors. RNA Metabolism in Neurodegenerative Diseases. Volume 20. Advances in Neurobiology; Springer International Publishing; Cham, Switzerland: 2018. pp. 173&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">29916020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F., Lu S., Yu H., Chen C., Melamed Z., Guo L., Shorter J., Da Cruz S., Cleveland D.W. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 2019;102:339&#x2013;357.e7. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N., Nero L., Lyons S., Ivanov P., Mittelmeier T., Bolger T., Buchan J. Stress Granule Assembly Can Facilitate but Is Not Required for TDP-43 Cytoplasmic Aggregation. Biomolecules. 2020;10:1367. doi: 10.3390/biom10101367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10101367</ArticleId><ArticleId IdType="pmc">PMC7650667</ArticleId><ArticleId IdType="pubmed">32992901</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z., Patten S.A. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front. Genet. 2019;9:712. doi: 10.3389/fgene.2018.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J., Birsa N., Milioto C., McLaughlin M., Ule A.M., Robaldo D., Eberle A.B., Kr&#xe4;uchi R., Bentham M., Brown A.-L., et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48:6889&#x2013;6905. doi: 10.1093/nar/gkaa410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa410</ArticleId><ArticleId IdType="pmc">PMC7337901</ArticleId><ArticleId IdType="pubmed">32479602</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolow D.T., Haynes S.R. Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation. Nucleic Acids Res. 1995;23:835&#x2013;843. doi: 10.1093/nar/23.5.835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/23.5.835</ArticleId><ArticleId IdType="pmc">PMC306767</ArticleId><ArticleId IdType="pubmed">7708500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.-W., Brent J.R., Tomlinson A., Shneider N.A., McCabe B.D. The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span. J. Clin. Investig. 2011;121:4118&#x2013;4126. doi: 10.1172/JCI57883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57883</ArticleId><ArticleId IdType="pmc">PMC3195475</ArticleId><ArticleId IdType="pubmed">21881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama H., Shimamura M., Tokuda T., Azuma Y., Yoshida T., Mizuno T., Nakagawa M., Fujikake N., Nagai Y., Yamaguchi M. Knockdown of the Drosophila Fused in Sarcoma (FUS) Homologue Causes Deficient Locomotive Behavior and Shortening of Motoneuron Terminal Branches. PLoS ONE. 2012;7:e39483. doi: 10.1371/journal.pone.0039483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039483</ArticleId><ArticleId IdType="pmc">PMC3378546</ArticleId><ArticleId IdType="pubmed">22724023</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamura M., Kyotani A., Azuma Y., Yoshida H., Binh Nguyen T., Mizuta I., Yoshida T., Mizuno T., Nakagawa M., Tokuda T., et al. Genetic link between Cabeza, a Drosophila homologue of Fused in Sarcoma (FUS), and the EGFR signaling pathway. Exp. Cell Res. 2014;326:36&#x2013;45. doi: 10.1016/j.yexcr.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2014.06.004</ArticleId><ArticleId IdType="pubmed">24928275</ArticleId></ArticleIdList></Reference><Reference><Citation>Frickenhaus M., Wagner M., Mallik M., Catinozzi M., Storkebaum E. Highly efficient cell-type-specific gene inactivation reveals a key function for the Drosophila FUS homolog cabeza in neurons. Sci. Rep. 2015;5:9107. doi: 10.1038/srep09107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep09107</ArticleId><ArticleId IdType="pmc">PMC5390904</ArticleId><ArticleId IdType="pubmed">25772687</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia R., Liu Y., Yang L., Gal J., Zhu H., Jia J. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol. Neurodegener. 2012;7:10. doi: 10.1186/1750-1326-7-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-10</ArticleId><ArticleId IdType="pmc">PMC3325858</ArticleId><ArticleId IdType="pubmed">22443542</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ckel S., Summerer A.K., Th&#xf6;mmes C.M., Pan X., Voigt A., Schulz J.B., Rasse T.M., Dormann D., Haass C., Kahle P.J. Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiol. Dis. 2015;74:76&#x2013;88. doi: 10.1016/j.nbd.2014.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.11.003</ArticleId><ArticleId IdType="pubmed">25447237</ArticleId></ArticleIdList></Reference><Reference><Citation>Machamer J.B., Collins S.E., Lloyd T.E. The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Hum. Mol. Genet. 2014;23:3810&#x2013;3822. doi: 10.1093/hmg/ddu094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu094</ArticleId><ArticleId IdType="pmc">PMC4065154</ArticleId><ArticleId IdType="pubmed">24569165</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., Diaz K., Guerra O., Altamirano P., Pagani W., Lodin D., Orozco G., Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwathmey K.G., Corcia P., McDermott C.J., Genge A., Sennf&#xe4;lt S., De Carvalho M., Ingre C. Diagnostic delay in amyotrophic lateral sclerosis. Euro J. Neurol. 2023;30:2595&#x2013;2601. doi: 10.1111/ene.15874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15874</ArticleId><ArticleId IdType="pubmed">37209406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Vullaganti M., Kwan J. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ. 2023;383:e075037. doi: 10.1136/bmj-2023-075037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-075037</ArticleId><ArticleId IdType="pmc">PMC10603569</ArticleId><ArticleId IdType="pubmed">37890889</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Amieva H., Petersen R.C., Ch&#xe9;telat G., Holtzman D.M., Hyman B.T., Nixon R.A., Jones D.T. Alzheimer disease. Nat. Rev. Dis. Primers. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E., Raaphorst J., Klein Twennaar M., de Visser M., Schmand B.A., de Haan R.J. The cognitive profile of ALS: A systematic review and meta-analysis update. J. Neurol. Neurosurg. Psychiatry. 2016;87:611&#x2013;619. doi: 10.1136/jnnp-2015-310734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310734</ArticleId><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T., Pinto-Grau M., Lonergan K., Elamin M., Bede P., Costello E., Hardiman O., Pender N. Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study. PLoS ONE. 2016;11:e0160850. doi: 10.1371/journal.pone.0160850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160850</ArticleId><ArticleId IdType="pmc">PMC4996502</ArticleId><ArticleId IdType="pubmed">27556398</ArticleId></ArticleIdList></Reference><Reference><Citation>Christidi F., Karavasilis E., Ferentinos P., Xirou S., Velonakis G., Rentzos M., Zouvelou V., Zalonis I., Efstathopoulos E., Kelekis N., et al. Investigating the neuroanatomical substrate of pathological laughing and crying in amyotrophic lateral sclerosis with multimodal neuroimaging techniques. Amyotroph. Lateral Scler. Front. Degener. 2018;19:12&#x2013;20. doi: 10.1080/21678421.2017.1386689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1386689</ArticleId><ArticleId IdType="pubmed">29034720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciurea A.V., Mohan A.G., Covache-Busuioc R.-A., Costin H.-P., Glavan L.-A., Corlatescu A.-D., Saceleanu V.M. Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer&#x2019;s, Parkinson&#x2019;s, and Huntington&#x2019;s Diseases and Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2023;24:10809. doi: 10.3390/ijms241310809.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310809</ArticleId><ArticleId IdType="pmc">PMC10341997</ArticleId><ArticleId IdType="pubmed">37445986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q.-Q., Ou R., Lin J., Zhang L., Hou Y., Cao B., Chen Y., Yang T., Shang H. Prevalence and Factors Related to Pathological Laughter and Crying in Patients with Amyotrophic Lateral Sclerosis. Front. Neurol. 2021;12:655674. doi: 10.3389/fneur.2021.655674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.655674</ArticleId><ArticleId IdType="pmc">PMC8505736</ArticleId><ArticleId IdType="pubmed">34650501</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Swash M. Diagnosis and differential diagnosis of MND/ALS: IFCN handbook chapter. Clin. Neurophysiol. Pract. 2024;9:27&#x2013;38. doi: 10.1016/j.cnp.2023.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnp.2023.12.003</ArticleId><ArticleId IdType="pmc">PMC10796809</ArticleId><ArticleId IdType="pubmed">38249779</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J., Swash M., De Carvalho M. Awaji Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis: A Systematic Review. Arch. Neurol. 2012;69:1410. doi: 10.1001/archneurol.2012.254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.254</ArticleId><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglass C.P., Kandler R.H., Shaw P.J., McDermott C.J. An evaluation of neurophysiological criteria used in the diagnosis of motor neuron disease. J. Neurol. Neurosurg. Psychiatry. 2010;81:646&#x2013;649. doi: 10.1136/jnnp.2009.197434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.197434</ArticleId><ArticleId IdType="pubmed">20522872</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho M.D., Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2009;10:53&#x2013;57. doi: 10.1080/17482960802521126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802521126</ArticleId><ArticleId IdType="pubmed">18985466</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashihara M. Fasciculation potentials in amyotrophic lateral sclerosis and the diagnostic yield of the Awaji algorithm. Muscle Nerve. 2012;45:175&#x2013;182. doi: 10.1002/mus.22299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22299</ArticleId><ArticleId IdType="pubmed">22246871</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J.-S., Bae J.S. AWAJI criteria are not always superior to the previous criteria: A meta-analysis. Muscle Nerve. 2015;51:822&#x2013;829. doi: 10.1002/mus.24575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24575</ArticleId><ArticleId IdType="pubmed">25597926</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., UK MND Clinical Studies Group Diagnosing ALS: The Gold Coast criteria and the role of EMG. Pract. Neurol. 2022;22:176&#x2013;178. doi: 10.1136/practneurol-2021-003256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2021-003256</ArticleId><ArticleId IdType="pmc">PMC9120398</ArticleId><ArticleId IdType="pubmed">34992096</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S. Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. Muscle Nerve. 2021;64:532&#x2013;537. doi: 10.1002/mus.27392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27392</ArticleId><ArticleId IdType="pubmed">34378224</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidovic M., M&#xfc;schen L.H., Brakemeier S., Machetanz G., Naumann M., Castro-Gomez S. Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis. Cells. 2023;12:736. doi: 10.3390/cells12050736.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050736</ArticleId><ArticleId IdType="pmc">PMC10000757</ArticleId><ArticleId IdType="pubmed">36899872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Stahl D.R., Lazo La Torre C., Murphy C., Young C., Shaw P.J., Leigh P.N., Al-Chalabi A. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph. Lateral Scler. Front. Degener. 2017;18:227&#x2013;232. doi: 10.1080/21678421.2016.1265565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebrehiwet P., Meng L., Rudnicki S.A., Sarocco P., Wei J., Wolff A.A., Chi&#xf2; A., Andrews J.A., Genge A., Jackson C.E., et al. MiToS and King&#x2019;s staging as clinical outcome measures in ALS: A retrospective analysis of the FORTITUDE-ALS trial. Amyotroph. Lateral Scler. Front. Degener. 2023;24:304&#x2013;310. doi: 10.1080/21678421.2022.2154678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2154678</ArticleId><ArticleId IdType="pubmed">36503310</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N., Domi T., Pozzi L., Lunetta C., Schito P., Spinelli E.G., Cabras S., Matteoni E., Consonni M., Bella E.D., et al. Update on recent advances in amyotrophic lateral sclerosis. J. Neurol. 2024;271:4693&#x2013;4723. doi: 10.1007/s00415-024-12435-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-024-12435-9</ArticleId><ArticleId IdType="pmc">PMC11233360</ArticleId><ArticleId IdType="pubmed">38802624</ArticleId></ArticleIdList></Reference><Reference><Citation>Huijbers M.G., Niks E.H., Klooster R., De Visser M., Kuks J.B., Veldink J.H., Klarenbeek P., Van Damme P., De Baets M.H., Van Der Maarel S.M., et al. Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscul. Disord. 2016;26:350&#x2013;353. doi: 10.1016/j.nmd.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2016.04.004</ArticleId><ArticleId IdType="pubmed">27133662</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., et al. Trial of Sodium Phenylbutyrate&#x2013;Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana I.C., Souza D.G., Souza D.O., Gee A., Zimmer E.R., Bongarzone S. A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases. J. Med. Chem. 2023;66:2330&#x2013;2346. doi: 10.1021/acs.jmedchem.2c01572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01572</ArticleId><ArticleId IdType="pmc">PMC9969404</ArticleId><ArticleId IdType="pubmed">36787643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Hombrados L., Molina-Torres G., Gal&#xe1;n-Mercant A., S&#xe1;nchez-Guerrero E., Gonz&#xe1;lez-S&#xe1;nchez M., Ruiz-Mu&#xf1;oz M. Systematic Review of Therapeutic Physical Exercise in Patients with Amyotrophic Lateral Sclerosis over Time. Int. J. Environ. Res. Public Health. 2021;18:1074. doi: 10.3390/ijerph18031074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031074</ArticleId><ArticleId IdType="pmc">PMC7908444</ArticleId><ArticleId IdType="pubmed">33530383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M.P. Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. P T. 2018;43:25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Watkins C., Cawson M., Hendrix S., Dickson S.P., Knowlton N., Timmons J., Manuel M., Cudkowicz M. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022;66:136&#x2013;141. doi: 10.1002/mus.27569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27569</ArticleId><ArticleId IdType="pmc">PMC9540225</ArticleId><ArticleId IdType="pubmed">35508892</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022;19:1248&#x2013;1258. doi: 10.1007/s13311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesenfarth M., Dorst J., Brenner D., Elmas Z., Parlak &#xd6;., Uzelac Z., Kandler K., Mayer K., Weiland U., Herrmann C., et al. Effects of tofersen treatment in patients with SOD1-ALS in a &#x201c;real-world&#x201d; setting&#x2014;A 12-month multicenter cohort study from the German early access program. EClinicalMedicine. 2024;69:102495. doi: 10.1016/j.eclinm.2024.102495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102495</ArticleId><ArticleId IdType="pmc">PMC10878861</ArticleId><ArticleId IdType="pubmed">38384337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.Y., Cho H.-Y., Oh J.-P., Park J., Bae S.-H., Park H., Kim E.J., Lee J.-H. Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS. Neurotherapeutics. 2023;20:1779&#x2013;1795. doi: 10.1007/s13311-023-01444-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-023-01444-7</ArticleId><ArticleId IdType="pmc">PMC10684847</ArticleId><ArticleId IdType="pubmed">37782409</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussicault L., Laffaire J., Schmitt P., Rinaudo P., Callizot N., Nabirotchkin S., Hajj R., Cohen D. Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis. J. Neurosci. Res. 2020;98:2435&#x2013;2450. doi: 10.1002/jnr.24714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24714</ArticleId><ArticleId IdType="pmc">PMC7693228</ArticleId><ArticleId IdType="pubmed">32815196</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L., Duddy W.J., Martinat C., Mariot V., Connolly O., Milla V., Anakor E., Ouandaogo Z.G., Millecamps S., Lain&#xe9; J., et al. Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles. J. Cachexia Sarcopenia Muscle. 2022;13:1385&#x2013;1402. doi: 10.1002/jcsm.12945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12945</ArticleId><ArticleId IdType="pmc">PMC8978001</ArticleId><ArticleId IdType="pubmed">35194965</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.X., Mercier P., Hartman J.J., Sykes B.D. Structural Basis of Tirasemtiv Activation of Fast Skeletal Muscle. J. Med. Chem. 2021;64:3026&#x2013;3034. doi: 10.1021/acs.jmedchem.0c01412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01412</ArticleId><ArticleId IdType="pubmed">33703886</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Cudkowicz M.E., Hardiman O., Cockroft B.M., Lee J.H., Malik F.I., Meng L., Rudnicki S.A., Wolff A.A., Andrews J.A., et al. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:584&#x2013;594. doi: 10.1080/21678421.2019.1612922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1612922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Fredericks M., Cannell M., Wang K., Sako D., Maguire M.C., Grenha R., Liharska K., Krishnan L., Bloom T., et al. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J. Clin. Investig. 2021;131:e138634. doi: 10.1172/JCI138634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138634</ArticleId><ArticleId IdType="pmc">PMC7880416</ArticleId><ArticleId IdType="pubmed">33586684</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;kkinen S., Chu S.A., Lee S.E. Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2020;145:105063. doi: 10.1016/j.nbd.2020.105063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105063</ArticleId><ArticleId IdType="pmc">PMC7572920</ArticleId><ArticleId IdType="pubmed">32890771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Krainer A.R., Cleveland D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019;42:385&#x2013;406. doi: 10.1146/annurev-neuro-070918-050501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R.H. Genetics of Amyotrophic Lateral Sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J., Li Y., Yuan B., Mitalipova M., Omer A., Corcoran S., Bakiasi G., Tsai L.-H., Aubourg P., Ransohoff R.M., et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 2016;22:1358&#x2013;1367. doi: 10.1038/nm.4189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4189</ArticleId><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Perdiguero E., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., Garner H., Trouillet C., De Bruijn M.F., Geissmann F., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547&#x2013;551. doi: 10.1038/nature13989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13989</ArticleId><ArticleId IdType="pmc">PMC5997177</ArticleId><ArticleId IdType="pubmed">25470051</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo F., Kok C.Y.L., Tan M.-J., Je H.S. Human pluripotent stem cell (hPSC)-derived microglia for the study of brain disorders. A comprehensive review of existing protocols. IBRO Neurosci. Rep. 2024;16:497&#x2013;508. doi: 10.1016/j.ibneur.2024.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibneur.2024.03.005</ArticleId><ArticleId IdType="pmc">PMC11035045</ArticleId><ArticleId IdType="pubmed">38655500</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P., Risse E., Tyzack G.E., Mitchell J.S., Taha D.M., Chen Y.-R., Newcombe J., Collinge J., Sidle K., Patani R. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143:430&#x2013;440. doi: 10.1093/brain/awz419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId><ArticleId IdType="pmc">PMC7009461</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78:186. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H., Yasuda D., Fujimori K., Morimoto S., Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol. Sci. 2020;41:99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A., Rao M.V., Veeranna, Nixon R.A. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb. Perspect. Biol. 2017;9:a018309. doi: 10.1101/cshperspect.a018309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a018309</ArticleId><ArticleId IdType="pmc">PMC5378049</ArticleId><ArticleId IdType="pubmed">28373358</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A., Boucraut J., Delmont E., Parlanti A., Grapperon A.-M., Attarian S., Verschueren A. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci. Rep. 2021;11:703. doi: 10.1038/s41598-020-80370-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80370-6</ArticleId><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I., Alcolea D., Montal V., Dols-Icardo O., Mu&#xf1;oz L., De Luna N., Tur&#xf3;n-Sans J., Cort&#xe9;s-Vicente E., S&#xe1;nchez-Saudin&#xf3;s M.B., Subirana A., et al. CSF sAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619&#x2013;e1628. doi: 10.1212/WNL.0000000000006383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Bampton A., Raciborska D., Talbot K., Turner M.R. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1215&#x2013;1220. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L., Tournoy J., Van Damme P., Poesen K. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L., An J., Kovalik T., Gendron T., Petrucelli L., Bowser R. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J. Neurol. Neurosurg. Psychiatry. 2020;91:350&#x2013;358. doi: 10.1136/jnnp-2019-321916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Toader C., Dobrin N., Brehar F.-M., Popa C., Covache-Busuioc R.-A., Glavan L.A., Costin H.P., Bratu B.-G., Corlatescu A.D., Popa A.A., et al. From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology. Int. J. Mol. Sci. 2023;24:16119. doi: 10.3390/ijms242216119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242216119</ArticleId><ArticleId IdType="pmc">PMC10671641</ArticleId><ArticleId IdType="pubmed">38003309</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani M., Della Valle I., Rossi S., Fabbrizio P., Margotta C., Nardo G., Cozzolino M., D&#x2019;Ambrosi N., Apolloni S. Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models. Neurotherapeutics. 2024;21:e00346. doi: 10.1016/j.neurot.2024.e00346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurot.2024.e00346</ArticleId><ArticleId IdType="pmc">PMC11070272</ArticleId><ArticleId IdType="pubmed">38493058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>